A Case of Appendiceal Adenocarcinoma with Clinical Benefit from FOLFOX and Bevacizumab

Publisher： Karger

E-ISSN： 1662-6575|2|2|111-115

ISSN： 1662-6575

Source： Case Reports in Oncology, Vol.2, Iss.2, 2009-07, pp. : 111-115

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Clinical Benefit from Trametinib in a Patient with Appendiceal Adenocarcinoma with a GNAS R201H Mutation

By  

Case Reports in Oncology, Vol. 10, Iss. 2, 2017-06 ,pp. : 548-552

Karger

Access to resources Recommend Favorite

Successful Treatment of Metastatic Anal Canal Adenocarcinoma with mFOLFOX6 + Bevacizumab

By  

Case Reports in Oncology, Vol. 9, Iss. 1, 2016-04 ,pp. : 249-254

Karger

Access to resources Recommend Favorite

CBDCA + Pemetrexed + Bevacizumab and Its Maintenance Chemotherapy in a Case of Solitary Breast Metastasis from a Lung Adenocarcinoma Resistant to Gefitinib

By  

Case Reports in Oncology, Vol. 5, Iss. 3, 2012-10 ,pp. : 546-553

Karger

Access to resources Recommend Favorite

A Case of High-Grade Neuroendocrine Carcinoma That Improved with Bevacizumab plus Modified FOLFOX6 as the Fourth-Line Chemotherapy

By  

Case Reports in Oncology, Vol. 4, Iss. 2, 2011-05 ,pp. : 260-266

Karger

Access to resources Recommend Favorite

Complete Response of Primary Bladder Adenocarcinoma with the FOLFOX4 Regimen

By  

Urologia Internationalis, Vol. 94, Iss. 3, 2013-11 ,pp. : 363-365

Karger

Access to resources Recommend Favorite